Nanobiotix (NANO) Q1 2026 earnings summary

Executive summary

• Completed a follow-on offering in May 2026, raising €86.1 million to accelerate platform development.

• Presented new clinical and preclinical data for JNJ-1900 (NBTXR3) and Nanoprimer platforms at major oncology conferences.

• FDA accepted a protocol amendment for the pivotal NANORAY-312 study, expediting final analysis.

Financial highlights

• Cash and cash equivalents totaled €42.1 million as of March 31, 2026.

• Proceeds from the follow-on offering, combined with existing cash, are expected to fund operations into 2029.

Outlook and guidance

• Current cash position and recent capital raise are projected to support working capital needs for operations into 2029, based on the current cash burn rate.